Hypertrophic cardiomyopathy, a fascinating and controversial disease,' 2 iS characterised by massive hypertrophy of the myocardium and is associated with various presentations ranging from complete absence of symptoms to sudden, unexpected death. There is a subgroup of patients who present with severe limiting symptoms of dyspnoea, angina, and syncope related partly to obstruction of the left ventricular outflow tract. Previously, the established therapy for these patients was a trial of ,B blockers, calcium channel blockers, and disopyramide administered in high doses, followed by septal myectomy for those intolerant of or unresponsive to medications.' 2 Recent reports have documented significant symptomatic improvement in many patients with dual chamber pacing,34 and the question has arisen whether permanent pacemakers should be considered in all patients with hypertrophic obstructive cardiomyopathy who have severe limiting symptoms despite medical treatment.
Pathophysiology of symptoms
It is important to understand the complex pathophysiological processes that contribute to dyspnoea, angina, and syncope in order to direct treatment for patients with hypertrophic cardiomyopathy. Impaired diastolic filling of the left or right ventricle in this condition has long been recognised as a major contributor to the symptoms. 56 Though the documented increase in left ventricular end diastolic pressure was initially believed to be due to increased chamber stiffness caused by the "hypertrophied inelastic muscle"78 recent insight into the process of ventricular relaxation9 has led to the conclusion that impaired relaxation may be of greater importance than increased chamber stiffness in explaining abnormalities of diastolic filling.'56 Myocardial relaxation is much impaired in hypertrophic cardiomyopathy and this impairment is believed to be caused by (a) abnormalities of calcium metabolism that lead to abnormal inactivation of the contractile elements, (b) a high systolic contraction load, (c) non-uniformity of relaxation, and (d) myocardial ischaemia.' 5 6 In addition to having severe abnormalities of diastolic function, many From the pathophysiological standpoint, myectomy favourably affects myocardial oxygen consumption and metabolism.2' Left ventricular end diastolic pressure is significantly decreased,'72' indicating an improvement in overall diastolic filling of the heart. These beneficial changes may occur through several mechanisms, including (a) improvement in ventricular relaxation due to abolition of the high systolic contraction load and relief of ischaemia, (b) decrease in left atrial driving pressure across the mitral valve because of a decrease in mitral regurgitation, and (c) improvement in chamber compliance by relief of ischaemia.' 6 Symptomatic improvement is significant, with 90% of patients improving by at least one functional class and 73% being completely free of symptoms on long-term follow up.14 15 Although there are no data from randomised trials to examine the effect of myectomy on survival, a 5 year survival rate of 93% has been reported for patients younger than 65 years,15 which is exceptional for a disease process with 3-4% annual mortality. For patients younger than 40 years, late survival was significantly better than for historical controls. '9 The prospects As is true for any new technique, the results of permanent pacing for hypertrophic obstructive cardiomyopathy must be comparable with those of accepted techniques before universal recommendations can be made. The experience with dual chamber pacing in patients with hypertrophic obstructive cardiomyopathy is limited. The decrease in gradient achieved by pacing is modest compared with that provided by surgical myectomy, and its effects on myocardial ischaemia and the stimulus for hypertrophy are unknown. The relatively high residual gradient may be important for these patients: a residual gradient >15 mm Hg was an independent predictor of mortality after surgical myectomy."5 It is not known how dual chamber pacing affects the degree of mitral regurgitation, which contributes substantially to symptoms of dyspnoea in many patients. The overall effect of dual chamber pacing on diastolic filling of the heart is unknown. Diastolic dysfunction, primarily caused by abnormalities of relaxation, is believed to be important in the pathophysiological process, and right ventricular pacing alone actually prolongs the rate of left ventricular relaxation. 22 We have only short-term follow up on a small number of patients and do not know whether the initial haemodynamic or symptomatic benefit will be sustained in the long term. There may be some unrecognised, harmful adaptation with sustained dual chamber pacing. The ventricular dilatation noted on short-term follow up after pacing may be beneficial initially but in the long term may be detrimental, because eventual ventricular dilatation and heart failure are other causes of death in these patients.2' Thus prospective studies to evaluate the efficacy of dual chamber pacing need to be performed before this treatment is used universally in patients with severely symptomatic hypertrophic obstructive cardiomyopathy. 
